\-\ Texto\\:\\ \ \(0\)\
\-\ bcva\\:\\ 20\\/20\\ \\-2\\ ou\\ \\ \\ \\(low\\ myope\\ ou\\)\ \(0\)\
\-\ color\\ vision\\ \\(pip\\)\\:\\ 10\\/14\\ od\\ \\ 11\\/14\\ os\ \(0\)\
\-\ red\\ desaturation\\:\\ 90\\%\\ od\ \(0\)\
\-\ white\\ light\\ brightness\\:\\ 75\\%\\ od\ \(0\)\
\-\ pupils\\:\\ 4\\-\\>3mm\\ ou\\,\\ \\ \\ \\ 2\\+\\ apd\\ od\ \(0\)\
\-\ motility\\:\\ fd\\ \\&\\ v\\ ou\ \(0\)\
\-\ visual\\ fields\\:\\ gross\\ defect\\ to\\ confrontation\\ 7\\-9\\ clock\\ hours\\ od\\;\\ full\\ os\ \(0\)\
\-\ iop\\:\\ 16\\ ou\ \(0\)\
\-\ sle\\:\\ normal\\ anterior\\ segment\\ ou\ \(0\)\
\-\ dfe\\:\\ \ \(0\)\
\-\ \\ \\ \\ \\ \\ lens\\/vitreous\\:\\ clear\\ ou\\ \ \(0\)\
\-\ \\ \\ \\ \\ \\ macula\\:\\ \\+flr\\,\\ flat\\ and\\ unremarkable\\ ou\ \(0\)\
\-\ \\ \\ \\ \\ \\ a\\/v\\:\ \(0\)\
\-\ \\ \\ \\ \\ \\ \\ \\ \\ normal\\ caliber\\ w\\/o\\ nicking\\,\\ tortuosity\\,\\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \ \(1\)\
\-\ \\ \\ \\ \\ \\ \\ \\ \\ attenuation\\,\\ or\\ sheathing\\ ou\ \(0\)\
\-\ \\ \\ \\ \\ \\ periphery\\:\\ \ \(0\)\
\-\ \\ \\ \\ \\ \\ \\ \\ \\ flat\\ and\\ unremarkable\\ ou\ \(0\)\
\-\ \\ \\ \\ \\ \\ disc\\:\\ \ \(0\)\
\-\ \\ \\ \\ \\ \\ \\ \\ \\ 0\\.1\\ c\\/d\\ ou\\ w\\/o\\ pallor\\/heme\ \(0\)\
\-\ \\ \\ \\ \\ \\ \\ \\ \\ slightly\\ increased\\ fullness\\/elevation\\ od\\,\\ but\\ \\ \\ \\ \\ \\ \ \(0\)\
\-\ \\ \\ \\ \\ \\ \\ \\ \\ sharp\\ disc\\ margins\\/clearly\\-defined\\ vessels\ \(1\)\
\-\ \\ \\ \\ \\ \\ \\ \\ \\ single\\ flat\\,\\ hypopigmented\\ lesion\\ just\\ inferior\\ \\ \\ \ \(1\)\
\-\ \\ \\ \\ \\ \\ \\ \\ \\ to\\ disc\\ margin\\ od\\ \\(1\\/5\\ dd\\)\ \(0\)\
\-\ trans\\-sphenoidal\\ surgical\\ debulking\\ \\(uncomplicated\\)\ \(0\)\
\-\ serology\\:\ \(0\)\
\-\ \\ \\ \\ \\ \\ bartonella\ \(0\)\
\-\ \\ \\ \\ \\ \\ lyme\ \(0\)\
\-\ \\ \\ \\ \\ \\ rpr\\/fta\ \(0\)\
\-\ mri\\ orbits\ \(0\)\
\-\ presumably\\ new\\-onset\\,\\ painless\\,\\ diffuse\\ r\\ monocular\\ field\\ loss\\ \\ w\\/\\ \\+apd\\ and\\ subtle\\ abnormalities\\ of\\ r\\ optic\\ disc\ \(0\)\
\-\ large\\ intrasellar\\ and\\ suprasellar\\ mass\\ lesion\ \(0\)\
\-\ pituitary\\ macroadenoma\\ \\-\\ null\\ cell\\ \\(non\\-secreting\\)\ \(0\)\
\-\ optic\\ nerve\\ disease\\:\ \(0\)\
\-\ \\ \\ \\ \\ \\ neuropathy\\:\\ compressive\\/infiltrative\\,\\ \\ \\ \\ \\ \ \(1\)\
\-\ \\ \\ \\ \\ \\ inflammatory\\,\\ ischemic\\,\\ toxic\ \(1\)\
\-\ \\ \\ \\ \\ \\ optic\\ nerve\\ drusen\ \(1\)\
\-\ retrobulbar\\ optic\\ neuritis\\ \ \(0\)\
\-\ neuroretinitis\\ \\(bartonella\\,\\ syphilis\\,\\ lyme\\)\ \(0\)\
\-\ intracranial\\ process\\:\ \(0\)\
\-\ \\ \\ \\ \\ \\ \\-\\ mass\\ \\(pit\\ adenoma\\,\\ meningioma\\,\\ glioma\\,\\ \\ \\ \\ \\ \\ \ \(1\)\
\-\ \\ \\ \\ \\ \\ craniopharygioma\\)\ \(1\)\
\-\ \\ \\ \\ \\ \\ \\-\\ aneurysm\\ \\(most\\ likely\\ ica\\)\ \(0\)\
\-\ \\ \\ \\ \\ \\ inflammation\\ \\(sarcoid\\,\\ ms\\)\ \(0\)\
\-\ retinal\\ dystrophy\\/degeneration\\:\ \(0\)\
\-\ \\ \\ \\ \\ \\ \\-\\ fundus\\ flavimaculatus\ \(1\)\
\-\ 21\\ y\\.o\\.\\ woman\\ reservist\\,\\ activated\\ \\&\\ deployed\\ into\\ iraq\\ in\\ march\\.\ \(0\)\
\-\ air\\ evacuated\\ to\\ germany\\ and\\ then\\ subsequently\\ to\\ wramc\\ in\\ mid\\ july\\ for\\ dyspnea\\.\ \(0\)\
\-\ pulmonology\\ evaluation\\ made\\ a\\ diagnosis\\ of\\ asthma\\,\\ and\\ she\\ was\\ started\\ on\\ po\\ steroid\\ burst\\ w\\/\\ taper\\,\\ albuterol\\,\\ advair\\ and\\ singulaire\\.\\ \\ \ \(0\)\
\-\ r\\-sided\\ visual\\ loss\\ \\(od\\)\\ started\\ shortly\\ after\\ initiating\\ these\\ asthma\\ meds\\ and\\ remained\\ stable\\ over\\ next\\ 1\\-2\\ weeks\\.\\ \\ she\\ then\\ reported\\ \\â\\€\\œi\\ can\\â\\€\\™t\\ see\\ person\\ standing\\ to\\ my\\ right\\â\\€\\\\.\\ \ \(0\)\
\-\ she\\ denied\\ any\\ sudden\\ onset\\ \\-\\ but\\ is\\ unable\\ to\\ pinpoint\\ the\\ moment\\ when\\ her\\ symptoms\\ began\\ nor\\ recall\\ what\\ she\\ was\\ doing\\;\\ no\\ \\â\\€\\œfalling\\ curtain\\â\\€\\\\.\ \(0\)\
\-\ no\\ central\\ vision\\ loss\\ ou\ \(0\)\
\-\ no\\ vision\\ changes\\ os\ \(0\)\
\-\ no\\ floaters\\,\\ photopsia\\ or\\ amaurosis\\ \ \(1\)\
\-\ no\\ headache\\,\\ eye\\ pain\\ or\\ photophobia\\ \ \(1\)\
\-\ no\\ gross\\ neurologic\\ symptoms\\ \\(diplopia\\,\\ dysarthria\\,\\ weakness\\,\\ parasthesias\\,\\ confusion\\)\ \(1\)\
\-\ pmh\\/psh\\:\\ \ \(0\)\
\-\ \\ \\ \\ \\ \\ recent\\ asthma\\ dx\ \(1\)\
\-\ fh\\:\\ \ \(0\)\
\-\ \\ \\ \\ \\ \\ non\\-contributory\ \(1\)\
\-\ social\\ hx\\:\ \(0\)\
\-\ \\ \\ \\ \\ \\ no\\ tobacco\\/rare\\ etoh\ \(0\)\
\-\ \\ \\ \\ \\ \\ 1\\ previous\\ sexual\\ partner\\ 2\\ years\\ ago\ \(1\)\
\-\ meds\\:\ \(0\)\
\-\ \\ \\ \\ \\ \\ po\\ prednisone\\ taper\\ \\(currently\\ 20mg\\ qd\\)\ \(0\)\
\-\ \\ \\ \\ \\ \\ albuterol\ \(0\)\
\-\ \\ \\ \\ \\ \\ singular\ \(0\)\
\-\ \\ \\ \\ \\ \\ advair\ \(0\)\
\-\ \\ \\ \\ \\ \\ ocp\\ \ \(0\)\
\-\ allergies\\:\\ \ \(0\)\
\-\ \\ \\ \\ \\ \\ pcn\ \(0\)\
\-\ 10\\-15\\%\\ of\\ all\\ intracranial\\ tumors\ \(2\)\
\-\ normal\\ volunteers\\ had\\ 10\\%\\ incidence\\ of\\ asymptomatic\\ adenomas\\ by\\ mri\ \(0\)\
\-\ found\\ in\\ 1\\.5\\-27\\%\\ of\\ autopsy\\ cases\ \(0\)\
\-\ patients\\ present\\ with\\ either\\:\ \(0\)\
\-\ \\ \\ \\ \\ \\ hormonal\\ abnormalities\ \(0\)\
\-\ \\ \\ \\ \\ \\ symptoms\\ of\\ compressive\\ lesion\\:\\ headache\\,\\ field\\ \\ \\ \\ \ \(0\)\
\-\ \\ \\ \\ \\ \\ defects\\ or\\ cranial\\ nerve\\ palsies\\ \\(cavernous\\ sinus\\ \\ \ \(1\)\
\-\ \\ \\ \\ \\ \\ invasion\\)\\ \ \(1\)\
\-\ genetic\\ association\\:\ \(0\)\
\-\ \\ \\ \\ \\ \\ men\\ type\\ 1\\:\\ \ \(0\)\
\-\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ 30\\%\\ of\\ patients\\ have\\ pit\\ adenoma\ \(1\)\
\-\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ triad\\ with\\ parathyroid\\ and\\ pancreatic\\ islet\\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \ \(0\)\
\-\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ tumors\ \(1\)\
\-\ \\ \\ \\ \\ \\ gsp\\:\ \(0\)\
\-\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ gene\\ that\\ encodes\\ alpha\\-subunit\\ of\\ \\ \\ \\ \\ \ \(0\)\
\-\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ gtp\\-binding\\ protein\\ gs\ \(0\)\
\-\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ mutation\\ leads\\ to\\ activation\\ of\\ camp\ \(0\)\
\-\ \\ \\ \\ \\ \\ present\\ in\\:\ \(0\)\
\-\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ 40\\%\\ of\\ gh\\-secretors\ \(0\)\
\-\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ 10\\%\\ of\\ null\\ cell\\ \\(non\\-secretors\\)\ \(1\)\
\-\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ 6\\%\\ of\\ acth\\-secretors\ \(0\)\
\-\ classification\\:\ \(2\)\
\-\ \\ \\ \\ \\ \\ based\\ on\\ size\\:\ \(0\)\
\-\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ macroadenoma\\ \\>\\ 1cm\ \(0\)\
\-\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ microadenoma\\ \\<\\ 1cm\ \(0\)\
\-\ \\ \\ \\ \\ \\ based\\ on\\ what\\ the\\ tumor\\ secretes\\:\ \(0\)\
\-\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ prolactin\\,\\ gonadotropin\\,\\ gh\\,\\ acth\\,\\ tsh\ \(0\)\
\-\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ nothin\\â\\€\\™\\ \\(null\\ cell\\)\ \(1\)\
\-\ surgery\\:\ \(7\)\
\-\ \\ \\ \\ \\ \\ for\\ most\\ non\\-prolactin\\ secreting\\ adenomas\ \(0\)\
\-\ \\ \\ \\ \\ \\ usually\\ trans\\-sphenoidal\\:\ \(0\)\
\-\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ mortality\\ \\<1\\%\ \(0\)\
\-\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ common\\ complications\\:\\ nasal\\ septal\\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \ \(0\)\
\-\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ perforation\\,\\ ant\\.\\ pit\\ insufficiency\\,\\ \\ \ \(1\)\
\-\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ transient\\ diabetes\\ insipidus\\,\\ csf\\ leak\ \(0\)\
\-\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ carotid\\ injury\\ and\\ vision\\ loss\\ are\\ rare\ \(0\)\
\-\ \\ \\ \\ \\ \\ success\\ measures\\ clinically\\ and\\ radiographically\ \(0\)\
\-\ \\ \\ \\ \\ \\ normalization\\ of\\ hormones\\ varies\\ with\\ type\\/size\\ of\\ \\ \\ \ \(0\)\
\-\ \\ \\ \\ \\ \\ tumor\ \(2\)\
\-\ \\ \\ \\ \\ \\ normalization\\ of\\ visual\\ fields\\ \\=\\ 16\\-53\\%\ \(0\)\
\-\ \\ \\ \\ \\ \\ improvement\\ of\\ visual\\ fields\\ \\=\\ 26\\-70\\%\ \(0\)\
\-\ treatment\\ of\\ prolactinomas\\:\ \(0\)\
\-\ \\ \\ \\ \\ \\ medical\\ \\(dopamine\\ agonists\\)\ \(0\)\
\-\ \\ \\ \\ \\ \\ \\-\\ prl\\ secretion\\ inhibited\\ by\\ dopamine\\ secretion\\ \\ \ \(0\)\
\-\ \\ \\ \\ \\ \\ from\\ the\\ hypothalamus\ \(1\)\
\-\ \\ \\ \\ \\ \\ \\-\\ decreases\\ tumor\\ size\\ \\ \\ \\ \\ \\ \\(70\\-90\\%\\ of\\ cases\\)\ \(0\)\
\-\ \\ \\ \\ \\ \\ \\-\\ normalizes\\ prl\\ levels\\ \\ \\ \\ \\ \\(70\\-90\\%\\ of\\ cases\\)\ \(0\)\
\-\ \\ \\ \\ \\ \\ \\-\\ restores\\ ovulation\\/menses\\ \\(70\\-90\\%\\ of\\ cases\\)\ \(0\)\
\-\ \\ \\ \\ \\ \\ \\-\\ improves\\ visual\\ fields\\ \\ \\ \\ \\(70\\-90\\%\\ of\\ cases\\)\ \(0\)\
\-\ \\ \\ \\ \\ \\ \\"reversible\\,\\ therefore\\ lifelong\\ tx\\ is\\ rule\\"\ \(0\)\
\-\ drugs\\:\ \(2\)\
\-\ \\ \\ \\ \\ \\ bromocriptine\\ \\(classic\\â\\€\\”used\\ for\\ decades\\)\ \(0\)\
\-\ \\ \\ \\ \\ \\ side\\ effects\\:\\ n\\/v\\,\\ dizziness\\,\\ postural\\ \\ \\ \\ \ \(0\)\
\-\ \\ \\ \\ \\ \\ hypotension\\,\\ ha\\â\\€\\™s\ \(0\)\
\-\ newer\\ agents\\:\ \(0\)\
\-\ \\ \\ \\ \\ \\ lisuride\ \(0\)\
\-\ \\ \\ \\ \\ \\ pergolide\ \(0\)\
\-\ \\ \\ \\ \\ \\ cabergoline\ \(0\)\
\-\ new\\ txs\\ for\\ non\\-prl\\ adenomas\\:\ \(0\)\
\-\ \\ \\ \\ \\ \\ gh\\-secretors\\:\ \(0\)\
\-\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ somatostatin\\ analogs\\:\\ octreotide\\ \\&\\ lanreotide\ \(0\)\
\-\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ reduce\\ gh\\ levels\\ in\\ 90\\%\\ of\\ pts\\ \ \(0\)\
\-\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ achieve\\ complete\\ suppression\\ in\\ 50\\%\\ of\\ pts\ \(1\)\
\-\ radiation\\:\ \(0\)\
\-\ \\ \\ \\ \\ \\ usually\\ reserved\\ for\\ residual\\ dz\\ or\\ recurrence\\ \\ \\ \ \(0\)\
\-\ \\ \\ \\ \\ \\ after\\ surgery\ \(1\)\
\-\ \\ \\ \\ \\ \\ average\\ total\\ dose\\ \\=\\ 45\\-50\\ gy\ \(0\)\
\-\ \\ \\ \\ \\ \\ control\\ rates\\ of\\ 85\\-95\\%\\ \\@\\ 10\\ years\ \(0\)\
\-\ 3\\ types\\:\ \(1\)\
\-\ \\ \\ \\ \\ \\ standard\ \(0\)\
\-\ \\ \\ \\ \\ \\ stereotactic\\ fractionated\ \(0\)\
\-\ \\ \\ \\ \\ \\ stereotactic\\ radiosurgery\\ \\(single\\ dose\\ \\/\\ gamma\\ \\ \\ \\ \\ \ \(0\)\
\-\ \\ \\ \\ \\ \\ knife\\)\ \(1\)\
\-\ disadvantages\\:\ \(0\)\
\-\ \\ \\ \\ \\ \\ \\ slower\\ reversal\\ of\\ neurologic\\ symptoms\ \(0\)\
\-\ \\ \\ \\ \\ \\ \\ slower\\ drop\\ in\\ hormonal\\ levels\ \(0\)\
\-\ \\ \\ \\ \\ \\ \\ hypopituitarism\\:\\ 50\\%\\ of\\ pts\\ will\\ have\\ at\\ least\\ \\ \\ \\ \\ \ \(0\)\
\-\ \\ \\ \\ \\ \\ \\ one\\ pit\\ hormone\\ deficiency\\ \\@\\ 5\\ yrs\\ \\ \\ \\ \\ \\ \\ lifelong\\ \\ \\ \ \(1\)\
\-\ \\ \\ \\ \\ \\ \\ follow\\-up\ \(1\)\
\-\ secondary\\ brain\\ tumor\\:\ \(0\)\
\-\ \\ \\ \\ \\ \\ \\ risk\\ of\\ 1\\.3\\-1\\.7\\%\\ \\@\\ 10\\ yrs\ \(0\)\
\-\ \\ \\ \\ \\ \\ \\ risk\\ of\\ 1\\.9\\-2\\.7\\%\\ \\@\\ 20\\ yrs\ \(0\)\
\-\ \\ \\ \\ \\ \\ \\ \\(relative\\ risk\\ of\\ 9\\.3\\-16\\ x\\ general\\ population\\)\ \(0\)\
\-\ \\ \\ \\ \\ \\ \\ radiation\\-induced\\ optic\\ neuropathy\\/retinopathy\ \(0\)\
\-\ \\ \\ \\ \\ \\ \\ low\\ risk\\:\\ 0\\.7\\-2\\%\ \(0\)\
\-\ srs\\(stereotactic\\ radiosurgery\\)\ \(0\)\
\-\ \\ \\ \\ \\ \\ \\ \\ quicker\\ drop\\ in\\ hormone\\ levels\ \(0\)\
\-\ \\ \\ \\ \\ \\ \\ \\ adverse\\ cns\\ effects\\ in\\ 28\\%\\ of\\ cases\\ at\\ 3\\ yrs\\ \\ \\ \\ \ \(0\)\
\-\ \\ \\ \\ \\ \\ \\ \\ compared\\ with\\ 0\\%\\ with\\ fsrt3\ \(0\)\
\-\ \\ \\ \\ \\ \\ \\ \\ \\"not\\ recommended\\ \\!\\!\\"\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ ou\\:\\ 0\\.08788411439118786\ \(0\)\
\-\ \\-\\:\\ 0\\.07420648340183136\ \(0\)\
\-\ \\:\\:\\ 0\\.06024919061783929\ \(0\)\
\-\ \\%\\:\\ 0\\.05312689321284668\ \(0\)\
\-\ od\\:\\ 0\\.0505342999238408\ \(0\)\
\-\ pit\\:\\ 0\\.03168112606757615\ \(0\)\
\-\ 70\\-90\\:\\ 0\\.03168112606757615\ \(0\)\
\-\ \\@\\:\\ 0\\.02665487874842201\ \(0\)\
\-\ yrs\\:\\ 0\\.02308878909298227\ \(0\)\
\-\ null\\:\\ 0\\.0230471658151356\ \(0\)\
\-\ visual\\:\\ 0\\.02064965885584858\ \(0\)\
\-\ fields\\:\\ 0\\.019857720002587745\ \(0\)\
\-\ pts\\:\\ 0\\.0189503624714403\ \(0\)\
\-\ gh\\-secretors\\:\\ 0\\.018796414550035178\ \(0\)\
\-\ prl\\:\\ 0\\.018796414550035178\ \(0\)\
\-\ stereotactic\\:\\ 0\\.018613388540764948\ \(0\)\
\-\ \\(\\:\\ 0\\.018482602803680866\ \(0\)\
\-\ \\)\\:\\ 0\\.018256827943197572\ \(0\)\
\-\ cases\\:\\ 0\\.01820987759476204\ \(0\)\
\-\ adenomas\\:\\ 0\\.018166388725066148\ \(0\)\
\-\ dopamine\\:\\ 0\\.017318488791911626\ \(0\)\
\-\ disc\\:\\ 0\\.016969025658912666\ \(0\)\
\-\ optic\\:\\ 0\\.016868682386374526\ \(0\)\
\-\ vision\\:\\ 0\\.016835752552285355\ \(0\)\
\-\ trans\\-sphenoidal\\:\\ 0\\.016453957644559463\ \(0\)\
\-\ os\\:\\ 0\\.01631752566288547\ \(0\)\
\-\ flat\\:\\ 0\\.01601979509870846\ \(0\)\
\-\ bartonella\\:\\ 0\\.015840563033788075\ \(0\)\
\-\ advair\\:\\ 0\\.0153647772100904\ \(0\)\
\-\ asthma\\:\\ 0\\.01509970318255138\ \(0\)\
\-\ levels\\:\\ 0\\.01504158376661818\ \(0\)\
\-\ gh\\:\\ 0\\.014976031886435912\ \(0\)\
\-\ taper\\:\\ 0\\.014647352398531311\ \(0\)\
\-\ normalization\\:\\ 0\\.014647352398531311\ \(0\)\
\-\ slower\\:\\ 0\\.014647352398531311\ \(0\)\
\-\ lifelong\\:\\ 0\\.014362637275664525\ \(0\)\
\-\ \\=\\:\\ 0\\.014343662314542113\ \(0\)\
\-\ radiosurgery\\:\\ 0\\.013683631452384068\ \(0\)\
\-\ albuterol\\:\\ 0\\.013498106128312362\ \(0\)\
\-\ secretion\\:\\ 0\\.013498106128312362\ \(0\)\
\-\ risk\\:\\ 0\\.013199175468482245\ \(0\)\
\-\ hormonal\\:\\ 0\\.013022320304614686\ \(0\)\
\-\ 10\\:\\ 0\\.012284111847961238\ \(0\)\
\-\ \\!\\:\\ 0\\.012205705694260516\ \(0\)\
\-\ macroadenoma\\:\\ 0\\.01202018037018881\ \(0\)\
\-\ \\,\\:\\ 0\\.011544139254468545\ \(0\)\
\-\ 1cm\\:\\ 0\\.011341174546908353\ \(0\)\
\-\ lyme\\:\\ 0\\.011277522173454875\ \(0\)\
\-\ meds\\:\\ 0\\.011215715058586534\ \(0\)\
\-\ drop\\:\\ 0\\.011215715058586534\ \(0\)\
\-\ effects\\:\\ 0\\.010633000058587213\ \(0\)\
\-\ loss\\:\\ 0\\.010577672377264135\ \(0\)\
\-\ po\\:\\ 0\\.010412991026102712\ \(0\)\
\-\ hormone\\:\\ 0\\.010330973369753468\ \(0\)\
\-\ w\\/o\\:\\ 0\\.010291118075484485\ \(0\)\
\-\ she\\:\\ 0\\.010229365208759797\ \(0\)\
\-\ nerve\\:\\ 0\\.009847375671068144\ \(0\)\
\-\ what\\:\\ 0\\.009619303477105177\ \(0\)\
\-\ \\&\\:\\ 0\\.00959932161665703\ \(0\)\
\-\ dose\\:\\ 0\\.0095345693008802\ \(0\)\
\-\ w\\/\\:\\ 0\\.009453074177596197\ \(0\)\
\-\ myope\\:\\ 0\\.009398207275017589\ \(0\)\
\-\ 10\\/14\\:\\ 0\\.009398207275017589\ \(0\)\
\-\ 11\\/14\\:\\ 0\\.009398207275017589\ \(0\)\
\-\ 4\\-\\:\\ 0\\.009398207275017589\ \(0\)\
\-\ 7\\-9\\:\\ 0\\.009398207275017589\ \(0\)\
\-\ lens\\/vitreous\\:\\ 0\\.009398207275017589\ \(0\)\
\-\ \\+flr\\:\\ 0\\.009398207275017589\ \(0\)\
\-\ a\\/v\\:\\ 0\\.009398207275017589\ \(0\)\
\-\ nicking\\:\\ 0\\.009398207275017589\ \(0\)\
\-\ sheathing\\:\\ 0\\.009398207275017589\ \(0\)\
\-\ c\\/d\\:\\ 0\\.009398207275017589\ \(0\)\
\-\ pallor\\/heme\\:\\ 0\\.009398207275017589\ \(0\)\
\-\ fullness\\/elevation\\:\\ 0\\.009398207275017589\ \(0\)\
\-\ margins\\/clearly\\-defined\\:\\ 0\\.009398207275017589\ \(0\)\
\-\ rpr\\/fta\\:\\ 0\\.009398207275017589\ \(0\)\
\-\ \\+apd\\:\\ 0\\.009398207275017589\ \(0\)\
\-\ compressive\\/infiltrative\\:\\ 0\\.009398207275017589\ \(0\)\
\-\ neuroretinitis\\:\\ 0\\.009398207275017589\ \(0\)\
\-\ dystrophy\\/degeneration\\:\\ 0\\.009398207275017589\ \(0\)\
\-\ flavimaculatus\\:\\ 0\\.009398207275017589\ \(0\)\
\-\ reservist\\:\\ 0\\.009398207275017589\ \(0\)\
\-\ singulaire\\:\\ 0\\.009398207275017589\ \(0\)\
\-\ curtain\\:\\ 0\\.009398207275017589\ \(0\)\
\-\ floaters\\:\\ 0\\.009398207275017589\ \(0\)\
\-\ photopsia\\:\\ 0\\.009398207275017589\ \(0\)\
\-\ amaurosis\\:\\ 0\\.009398207275017589\ \(0\)\
\-\ tobacco\\/rare\\:\\ 0\\.009398207275017589\ \(0\)\
\-\ \\-allergies\\:\\ 0\\.009398207275017589\ \(0\)\
\-\ pcn\\:\\ 0\\.009398207275017589\ \(0\)\
\-\ volunteers\\:\\ 0\\.009398207275017589\ \(0\)\
\-\ 1\\.5\\-27\\:\\ 0\\.009398207275017589\ \(0\)\
\-\ gsp\\:\\ 0\\.009398207275017589\ \(0\)\
\-\ alpha\\-subunit\\:\\ 0\\.009398207275017589\ \(0\)\
\-\ gtp\\-binding\\:\\ 0\\.009398207275017589\ \(0\)\
\-\ non\\-secretors\\:\\ 0\\.009398207275017589\ \(0\)\
\-\ acth\\-secretors\\:\\ 0\\.009398207275017589\ \(0\)\
\-\ secretes\\:\\ 0\\.009398207275017589\ \(0\)\
\-\ nothin\\:\\ 0\\.009398207275017589\ \(0\)\
\-\ non\\-prolactin\\:\\ 0\\.009398207275017589\ \(0\)\
\-\ type\\/size\\:\\ 0\\.009398207275017589\ \(0\)\
\-\ 16\\-53\\:\\ 0\\.009398207275017589\ \(0\)\
\-\ 26\\-70\\:\\ 0\\.009398207275017589\ \(0\)\
\-\ restores\\:\\ 0\\.009398207275017589\ \(0\)\
\-\ ovulation\\/menses\\:\\ 0\\.009398207275017589\ \(0\)\
\-\ classic\\â\\€\\”used\\:\\ 0\\.009398207275017589\ \(0\)\
\-\ lisuride\\:\\ 0\\.009398207275017589\ \(0\)\
\-\ pergolide\\:\\ 0\\.009398207275017589\ \(0\)\
\-\ cabergoline\\:\\ 0\\.009398207275017589\ \(0\)\
\-\ txs\\:\\ 0\\.009398207275017589\ \(0\)\
\-\ non\\-prl\\:\\ 0\\.009398207275017589\ \(0\)\
\-\ lanreotide\\:\\ 0\\.009398207275017589\ \(0\)\
\-\ fractionated\\:\\ 0\\.009398207275017589\ \(0\)\
\-\ 1\\.3\\-1\\.7\\:\\ 0\\.009398207275017589\ \(0\)\
\-\ 1\\.9\\-2\\.7\\:\\ 0\\.009398207275017589\ \(0\)\
\-\ 9\\.3\\-16\\:\\ 0\\.009398207275017589\ \(0\)\
\-\ neuropathy\\/retinopathy\\:\\ 0\\.009398207275017589\ \(0\)\
\-\ 0\\.7\\-2\\:\\ 0\\.009398207275017589\ \(0\)\
\-\ srs\\:\\ 0\\.009398207275017589\ \(0\)\
\-\ fsrt3\\:\\ 0\\.009398207275017589\ \(0\)\
\-\ field\\:\\ 0\\.009349043976808495\ \(0\)\
\-\ symptoms\\:\\ 0\\.009081694997433429\ \(0\)\
\-\ gross\\:\\ 0\\.008679288476765988\ \(0\)\
\-\ bcva\\:\\ 0\\.008659244395955813\ \(0\)\
\-\ brightness\\:\\ 0\\.008659244395955813\ \(0\)\
\-\ dfe\\:\\ 0\\.008659244395955813\ \(0\)\
\-\ monocular\\:\\ 0\\.008659244395955813\ \(0\)\
\-\ non\\-secreting\\:\\ 0\\.008659244395955813\ \(0\)\
\-\ \\-intracranial\\:\\ 0\\.008659244395955813\ \(0\)\
\-\ craniopharygioma\\:\\ 0\\.008659244395955813\ \(0\)\
\-\ encodes\\:\\ 0\\.008659244395955813\ \(0\)\
\-\ prolactinomas\\:\\ 0\\.008659244395955813\ \(0\)\
\-\ inhibited\\:\\ 0\\.008659244395955813\ \(0\)\
\-\ normalizes\\:\\ 0\\.008659244395955813\ \(0\)\
\-\ 45\\-50\\:\\ 0\\.008659244395955813\ \(0\)\
\-\ 85\\-95\\:\\ 0\\.008659244395955813\ \(0\)\
\-\ 90\\:\\ 0\\.008588543030244035\ \(0\)\
\-\ tumor\\:\\ 0\\.0084956601348009\ \(0\)\
\-\ r\\:\\ 0\\.008275148168093403\ \(0\)\
\-\ \\-2\\:\\ 0\\.008226978822279732\ \(0\)\
\-\ apd\\:\\ 0\\.008226978822279732\ \(0\)\
\-\ fd\\:\\ 0\\.008226978822279732\ \(0\)\
\-\ macula\\:\\ 0\\.008226978822279732\ \(0\)\
\-\ 1\\/5\\:\\ 0\\.008226978822279732\ \(0\)\
\-\ \\-optic\\:\\ 0\\.008226978822279732\ \(0\)\
\-\ activated\\:\\ 0\\.008226978822279732\ \(0\)\
\-\ r\\-sided\\:\\ 0\\.008226978822279732\ \(0\)\
\-\ pinpoint\\:\\ 0\\.008226978822279732\ \(0\)\
\-\ partner\\:\\ 0\\.008226978822279732\ \(0\)\
\-\ singular\\:\\ 0\\.008226978822279732\ \(0\)\
\-\ gs\\:\\ 0\\.008226978822279732\ \(0\)\
\-\ ant\\:\\ 0\\.008226978822279732\ \(0\)\
\-\ disadvantages\\:\\ 0\\.008226978822279732\ \(0\)\
\-\ radiation\\-induced\\:\\ 0\\.008226978822279732\ \(0\)\
\-\ quicker\\:\\ 0\\.008226978822279732\ \(0\)\
\-\ \\â\\€\\™\\:\\ 0\\.008168529018055828\ \(0\)\
\-\ started\\:\\ 0\\.008127019441409465\ \(0\)\
\-\ confrontation\\:\\ 0\\.007920281516894037\ \(0\)\
\-\ moment\\:\\ 0\\.007920281516894037\ \(0\)\
\-\ 20mg\\:\\ 0\\.007920281516894037\ \(0\)\
\-\ ocp\\:\\ 0\\.007920281516894037\ \(0\)\
\-\ somatostatin\\:\\ 0\\.007920281516894037\ \(0\)\
\-\ analogs\\:\\ 0\\.007920281516894037\ \(0\)\
\-\ dd\\:\\ 0\\.0076823886050452\ \(0\)\
\-\ initiating\\:\\ 0\\.0076823886050452\ \(0\)\
\-\ pmh\\/psh\\:\\ 0\\.0076823886050452\ \(0\)\
\-\ agonists\\:\\ 0\\.0076823886050452\ \(0\)\
\-\ hypopituitarism\\:\\ 0\\.0076823886050452\ \(0\)\
\-\ adenoma\\:\\ 0\\.007608729961206849\ \(0\)\
\-\ neurologic\\:\\ 0\\.007608729961206849\ \(0\)\
\-\ clock\\:\\ 0\\.007488015943217956\ \(0\)\
\-\ drusen\\:\\ 0\\.007488015943217956\ \(0\)\
\-\ camp\\:\\ 0\\.007488015943217956\ \(0\)\
\-\ gonadotropin\\:\\ 0\\.007488015943217956\ \(0\)\
\-\ insipidus\\:\\ 0\\.007488015943217956\ \(0\)\
\-\ bromocriptine\\:\\ 0\\.007488015943217956\ \(0\)\
\-\ achieve\\:\\ 0\\.007488015943217956\ \(0\)\
\-\ single\\:\\ 0\\.007385203178017978\ \(0\)\
\-\ cell\\:\\ 0\\.007382432979471705\ \(0\)\
\-\ iop\\:\\ 0\\.0073236761992656555\ \(0\)\
\-\ hypopigmented\\:\\ 0\\.0073236761992656555\ \(0\)\
\-\ germany\\:\\ 0\\.0073236761992656555\ \(0\)\
\-\ pulmonology\\:\\ 0\\.0073236761992656555\ \(0\)\
\-\ parasthesias\\:\\ 0\\.0073236761992656555\ \(0\)\
\-\ activation\\:\\ 0\\.0073236761992656555\ \(0\)\
\-\ gy\\:\\ 0\\.0073236761992656555\ \(0\)\
\-\ desaturation\\:\\ 0\\.007181318637832263\ \(0\)\
\-\ retrobulbar\\:\\ 0\\.007181318637832263\ \(0\)\
\-\ palsies\\:\\ 0\\.007181318637832263\ \(0\)\
\-\ hormones\\:\\ 0\\.007181318637832263\ \(0\)\
\-\ octreotide\\:\\ 0\\.007181318637832263\ \(0\)\
\-\ serology\\:\\ 0\\.007055750369541874\ \(0\)\
\-\ intrasellar\\:\\ 0\\.007055750369541874\ \(0\)\
\-\ burst\\:\\ 0\\.007055750369541874\ \(0\)\
\-\ microadenoma\\:\\ 0\\.007055750369541874\ \(0\)\
\-\ n\\/v\\:\\ 0\\.007055750369541874\ \(0\)\
\-\ newer\\:\\ 0\\.007055750369541874\ \(0\)\
\-\ \\<\\:\\ 0\\.00703212265991853\ \(0\)\
\-\ based\\:\\ 0\\.006948167083724862\ \(0\)\
\-\ new\\-onset\\:\\ 0\\.006943425725983425\ \(0\)\
\-\ fh\\:\\ 0\\.006943425725983425\ \(0\)\
\-\ sexual\\:\\ 0\\.006943425725983425\ \(0\)\
\-\ acth\\:\\ 0\\.006943425725983425\ \(0\)\
\-\ 50\\:\\ 0\\.006931765493910031\ \(0\)\
\-\ tumors\\:\\ 0\\.006843744899084223\ \(0\)\
\-\ 20\\/20\\:\\ 0\\.006841815726192034\ \(0\)\
\-\ wramc\\:\\ 0\\.006841815726192034\ \(0\)\
\-\ improves\\:\\ 0\\.006841815726192034\ \(0\)\
\-\ \\â\\€\\œ\\:\\ 0\\.00680490600805791\ \(0\)\
\-\ \\â\\€\\\\:\\ 0\\.006766761946755617\ \(0\)\
\-\ tortuosity\\:\\ 0\\.006749053064156181\ \(0\)\
\-\ iraq\\:\\ 0\\.006749053064156181\ \(0\)\
\-\ recall\\:\\ 0\\.006749053064156181\ \(0\)\
\-\ secreting\\:\\ 0\\.006749053064156181\ \(0\)\
\-\ abnormalities\\:\\ 0\\.006692461879953553\ \(0\)\
\-\ 0\\.1\\:\\ 0\\.006663719687105502\ \(0\)\
\-\ dz\\:\\ 0\\.006663719687105502\ \(0\)\
\-\ motility\\:\\ 0\\.00658471332020388\ \(0\)\
\-\ islet\\:\\ 0\\.00658471332020388\ \(0\)\
\-\ adverse\\:\\ 0\\.00658471332020388\ \(0\)\
\-\ prolactin\\:\\ 0\\.006511160152307343\ \(0\)\
\-\ 1\\:\\ 0\\.0065031760169287\ \(0\)\
\-\ then\\:\\ 0\\.006483937907083347\ \(0\)\
\-\ debulking\\:\\ 0\\.006442355758770487\ \(0\)\
\-\ autopsy\\:\\ 0\\.006442355758770487\ \(0\)\
\-\ hypothalamus\\:\\ 0\\.006442355758770487\ \(0\)\
\-\ no\\:\\ 0\\.0064212250052522535\ \(0\)\
\-\ my\\:\\ 0\\.0063167874904801\ \(0\)\
\-\ dysarthria\\:\\ 0\\.0063167874904801\ \(0\)\
\-\ postural\\:\\ 0\\.006259146529637588\ \(0\)\
\-\ headache\\:\\ 0\\.00625796468564136\ \(0\)\
\-\ 10\\-15\\:\\ 0\\.006204462846921649\ \(0\)\
\-\ decreases\\:\\ 0\\.006204462846921649\ \(0\)\
\-\ suppression\\:\\ 0\\.006204462846921649\ \(0\)\
\-\ pip\\:\\ 0\\.006152447746527798\ \(0\)\
\-\ triad\\:\\ 0\\.006152447746527798\ \(0\)\
\-\ size\\:\\ 0\\.0061084773376946086\ \(0\)\
\-\ presumably\\:\\ 0\\.006102852847130258\ \(0\)\
\-\ syphilis\\:\\ 0\\.006102852847130258\ \(0\)\
\-\ retinal\\:\\ 0\\.006102852847130258\ \(0\)\
\-\ evacuated\\:\\ 0\\.006102852847130258\ \(0\)\
\-\ gene\\:\\ 0\\.006102852847130258\ \(0\)\
\-\ reversible\\:\\ 0\\.006102852847130258\ \(0\)\
\-\ ha\\:\\ 0\\.006055462908355382\ \(0\)\
\-\ reserved\\:\\ 0\\.006055462908355382\ \(0\)\
\-\ \\>\\:\\ 0\\.006053662078184572\ \(0\)\
\-\ unremarkable\\:\\ 0\\.006032124560089681\ \(0\)\
\-\ 3mm\\:\\ 0\\.006010090185094405\ \(0\)\
\-\ deployed\\:\\ 0\\.006010090185094405\ \(0\)\
\-\ qd\\:\\ 0\\.006010090185094405\ \(0\)\
\-\ dx\\:\\ 0\\.005966569935072811\ \(0\)\
\-\ etoh\\:\\ 0\\.005966569935072811\ \(0\)\
\-\ varies\\:\\ 0\\.005966569935072811\ \(0\)\
\-\ orbits\\:\\ 0\\.005924756808043726\ \(0\)\
\-\ march\\:\\ 0\\.005884521916804018\ \(0\)\
\-\ july\\:\\ 0\\.005884521916804018\ \(0\)\
\-\ person\\:\\ 0\\.005884521916804018\ \(0\)\
\-\ reversal\\:\\ 0\\.005884521916804018\ \(0\)\
\-\ decades\\:\\ 0\\.005845750441142105\ \(0\)\
\-\ mutation\\:\\ 0\\.005808339652430728\ \(0\)\
\-\ neuritis\\:\\ 0\\.005772197273245567\ \(0\)\
\-\ parathyroid\\:\\ 0\\.005772197273245567\ \(0\)\
\-\ knife\\:\\ 0\\.005737240106056879\ \(0\)\
\-\ compressive\\:\\ 0\\.005638761086727438\ \(0\)\
\-\ tx\\:\\ 0\\.005638761086727438\ \(0\)\
\-\ neuropathy\\:\\ 0\\.005607857529293267\ \(0\)\
\-\ photophobia\\:\\ 0\\.005607857529293267\ \(0\)\
\-\ hypotension\\:\\ 0\\.005577824611418324\ \(0\)\
\-\ lesion\\:\\ 0\\.005566807759063288\ \(0\)\
\-\ success\\:\\ 0\\.005548614617614364\ \(0\)\
\-\ usually\\:\\ 0\\.005532896063681789\ \(0\)\
\-\ gamma\\:\\ 0\\.005520183650575813\ \(0\)\
\-\ confusion\\:\\ 0\\.005465499967859873\ \(0\)\
\-\ leak\\:\\ 0\\.005465499967859873\ \(0\)\
\-\ 0\\:\\ 0\\.005465499967859873\ \(0\)\
\-\ sle\\:\\ 0\\.005439175220961824\ \(0\)\
\-\ doing\\:\\ 0\\.005413484867466023\ \(0\)\
\-\ prednisone\\:\\ 0\\.005388399049331488\ \(0\)\
\-\ caliber\\:\\ 0\\.005363889968068482\ \(0\)\
\-\ years\\:\\ 0\\.005350198586393353\ \(0\)\
\-\ toxic\\:\\ 0\\.0053399316995694866\ \(0\)\
\-\ ica\\:\\ 0\\.0053399316995694866\ \(0\)\
\-\ agents\\:\\ 0\\.0053399316995694866\ \(0\)\
\-\ or\\:\\ 0\\.005338607403857716\ \(0\)\
\-\ diplopia\\:\\ 0\\.005316500029293607\ \(0\)\
\-\ social\\:\\ 0\\.005316500029293607\ \(0\)\
\-\ average\\:\\ 0\\.005316500029293607\ \(0\)\
\-\ rates\\:\\ 0\\.005293572305177441\ \(0\)\
\-\ fundus\\:\\ 0\\.00527112730603263\ \(0\)\
\-\ 1\\-2\\:\\ 0\\.005227607056011036\ \(0\)\
\-\ classification\\:\\ 0\\.005206495513051356\ \(0\)\
\-\ shortly\\:\\ 0\\.0051857939289819514\ \(0\)\
\-\ falling\\:\\ 0\\.0051455590377422426\ \(0\)\
\-\ men\\:\\ 0\\.0051455590377422426\ \(0\)\
\-\ reduce\\:\\ 0\\.0051455590377422426\ \(0\)\
\-\ uncomplicated\\:\\ 0\\.0051259970562196455\ \(0\)\
\-\ periphery\\:\\ 0\\.005087918076899732\ \(0\)\
\-\ leads\\:\\ 0\\.005087918076899732\ \(0\)\
\-\ low\\:\\ 0\\.005066456402700212\ \(0\)\
\-\ radiographically\\:\\ 0\\.005033234394183793\ \(0\)\
\-\ drugs\\:\\ 0\\.005033234394183793\ \(0\)\
\-\ v\\:\\ 0\\.004998277226995103\ \(0\)\
\-\ pupils\\:\\ 0\\.004981219293789942\ \(0\)\
\-\ genetic\\:\\ 0\\.004981219293789942\ \(0\)\
\-\ suprasellar\\:\\ 0\\.004964430000646936\ \(0\)\
\-\ remained\\:\\ 0\\.004964430000646936\ \(0\)\
\-\ mortality\\:\\ 0\\.004964430000646936\ \(0\)\
\-\ septal\\:\\ 0\\.004964430000646936\ \(0\)\
\-\ tsh\\:\\ 0\\.004947901017133114\ \(0\)\
\-\ sharp\\:\\ 0\\.0049316243943924015\ \(0\)\
\-\ transient\\:\\ 0\\.0049316243943924015\ \(0\)\
\-\ deficiency\\:\\ 0\\.004915592542191399\ \(0\)\
\-\ dizziness\\:\\ 0\\.004884234455617525\ \(0\)\
\-\ ms\\:\\ 0\\.004868894650231491\ \(0\)\
\-\ nor\\:\\ 0\\.004868894650231491\ \(0\)\
\-\ standing\\:\\ 0\\.004853772438086549\ \(0\)\
\-\ insufficiency\\:\\ 0\\.0048388617323565485\ \(0\)\
\-\ steroid\\:\\ 0\\.004809651738552589\ \(0\)\
\-\ red\\:\\ 0\\.004753528355305871\ \(0\)\
\-\ population\\:\\ 0\\.004753528355305871\ \(0\)\
\-\ patients\\:\\ 0\\.004715510872848669\ \(0\)\
\-\ perforation\\:\\ 0\\.004687289782697121\ \(0\)\
\-\ sarcoid\\:\\ 0\\.004674521988404247\ \(0\)\
\-\ protein\\:\\ 0\\.004674521988404247\ \(0\)\
\-\ 75\\:\\ 0\\.004661905295816825\ \(0\)\
\-\ 2\\+\\:\\ 0\\.004661905295816825\ \(0\)\
\-\ standard\\:\\ 0\\.004661905295816825\ \(0\)\
\-\ cns\\:\\ 0\\.004661905295816825\ \(0\)\
\-\ types\\:\\ 0\\.004649436170269712\ \(0\)\
\-\ next\\:\\ 0\\.004624927089006707\ \(0\)\
\-\ began\\:\\ 0\\.004612880654834071\ \(0\)\
\-\ painless\\:\\ 0\\.004577537150231831\ \(0\)\
\-\ pituitary\\:\\ 0\\.004566011653319021\ \(0\)\
\-\ least\\:\\ 0\\.004566011653319021\ \(0\)\
\-\ residual\\:\\ 0\\.0045211166795982045\ \(0\)\
\-\ hx\\:\\ 0\\.004510182244451946\ \(0\)\
\-\ nasal\\:\\ 0\\.004510182244451946\ \(0\)\
\-\ diabetes\\:\\ 0\\.004510182244451946\ \(0\)\
\-\ \\/\\:\\ 0\\.004499358820716321\ \(0\)\
\-\ \\`\\`\\:\\ 0\\.004477899867018799\ \(0\)\
\-\ pancreatic\\:\\ 0\\.004457131594602199\ \(0\)\
\-\ color\\:\\ 0\\.0044468310499201765\ \(0\)\
\-\ ischemic\\:\\ 0\\.0044366290765554105\ \(0\)\
\-\ denied\\:\\ 0\\.0044366290765554105\ \(0\)\
\-\ association\\:\\ 0\\.004426523805814959\ \(0\)\
\-\ surgery\\:\\ 0\\.004424305041279904\ \(0\)\
\-\ \\'\\'\\:\\ 0\\.0043917899829045695\ \(0\)\
\-\ invasion\\:\\ 0\\.00438703417715787\ \(0\)\
\-\ relative\\:\\ 0\\.004339644238382994\ \(0\)\
\-\ \\;\\:\\ 0\\.004318595284547108\ \(0\)\
\-\ dyspnea\\:\\ 0\\.004312189551706645\ \(0\)\
\-\ therefore\\:\\ 0\\.00430319289003728\ \(0\)\
\-\ 28\\:\\ 0\\.004294271515122018\ \(0\)\
\-\ margin\\:\\ 0\\.004285424177366479\ \(0\)\
\-\ normal\\:\\ 0\\.004284474801489662\ \(0\)\
\-\ 3\\:\\ 0\\.004266472338393475\ \(0\)\
\-\ light\\:\\ 0\\.004250751265100423\ \(0\)\
\-\ improvement\\:\\ 0\\.004250751265100423\ \(0\)\
\-\ cavernous\\:\\ 0\\.0042254671215851605\ \(0\)\
\-\ t\\:\\ 0\\.004217170596593631\ \(0\)\
\-\ sudden\\:\\ 0\\.004208938138071339\ \(0\)\
\-\ unable\\:\\ 0\\.004208938138071339\ \(0\)\
\-\ most\\:\\ 0\\.004206471517543872\ \(0\)\
\-\ mri\\:\\ 0\\.004186089242888315\ \(0\)\
\-\ subtle\\:\\ 0\\.004184615453885655\ \(0\)\
\-\ defects\\:\\ 0\\.004184615453885655\ \(0\)\
\-\ incidence\\:\\ 0\\.0041766296631296235\ \(0\)\
\-\ control\\:\\ 0\\.004153025051320227\ \(0\)\
\-\ subsequently\\:\\ 0\\.0041299317711697165\ \(0\)\
\-\ 16\\:\\ 0\\.004122343852439584\ \(0\)\
\-\ 21\\:\\ 0\\.004122343852439584\ \(0\)\
\-\ present\\:\\ 0\\.0041151572578500654\ \(0\)\
\-\ glioma\\:\\ 0\\.004107328138279948\ \(0\)\
\-\ carotid\\:\\ 0\\.004085193819038552\ \(0\)\
\-\ in\\:\\ 0\\.004043257005610122\ \(0\)\
\-\ clinically\\:\\ 0\\.003994258232138877\ \(0\)\
\-\ segment\\:\\ 0\\.003974330585004386\ \(0\)\
\-\ recurrence\\:\\ 0\\.003974330585004386\ \(0\)\
\-\ either\\:\\ 0\\.003967769960724665\ \(0\)\
\-\ cranial\\:\\ 0\\.003961249462838272\ \(0\)\
\-\ have\\:\\ 0\\.0039454969687955045\ \(0\)\
\-\ full\\:\\ 0\\.0039355591093424725\ \(0\)\
\-\ total\\:\\ 0\\.003922942416755049\ \(0\)\
\-\ measures\\:\\ 0\\.0038981483206310973\ \(0\)\
\-\ for\\:\\ 0\\.0038865039906328096\ \(0\)\
\-\ but\\:\\ 0\\.00388593454378153\ \(0\)\
\-\ inflammation\\:\\ 0\\.0038739177757722955\ \(0\)\
\-\ compared\\:\\ 0\\.003856099565778969\ \(0\)\
\-\ intracranial\\:\\ 0\\.0038502257322917937\ \(0\)\
\-\ general\\:\\ 0\\.003838574271170056\ \(0\)\
\-\ 40\\:\\ 0\\.0038327959476419757\ \(0\)\
\-\ eye\\:\\ 0\\.0038213324169636582\ \(0\)\
\-\ mid\\:\\ 0\\.003809990841052085\ \(0\)\
\-\ just\\:\\ 0\\.0038043649806034246\ \(0\)\
\-\ csf\\:\\ 0\\.0038043649806034246\ \(0\)\
\-\ rule\\:\\ 0\\.0038043649806034246\ \(0\)\
\-\ recommended\\:\\ 0\\.0037766725643952575\ \(0\)\
\-\ after\\:\\ 0\\.00376972537869766\ \(0\)\
\-\ i\\:\\ 0\\.0037657939181540614\ \(0\)\
\-\ stable\\:\\ 0\\.0037550251591066163\ \(0\)\
\-\ of\\:\\ 0\\.003726134353880227\ \(0\)\
\-\ slightly\\:\\ 0\\.003682543985348692\ \(0\)\
\-\ vessels\\:\\ 0\\.003667633279618692\ \(0\)\
\-\ attenuation\\:\\ 0\\.0036627090303049453\ \(0\)\
\-\ made\\:\\ 0\\.0036288618039567785\ \(0\)\
\-\ currently\\:\\ 0\\.00360999231877618\ \(0\)\
\-\ complications\\:\\ 0\\.00360999231877618\ \(0\)\
\-\ aneurysm\\:\\ 0\\.0036006813593212183\ \(0\)\
\-\ hours\\:\\ 0\\.0035822999025680135\ \(0\)\
\-\ previous\\:\\ 0\\.003537686778969399\ \(0\)\
\-\ rare\\:\\ 0\\.003537686778969399\ \(0\)\
\-\ process\\:\\ 0\\.0035075324998237894\ \(0\)\
\-\ meningioma\\:\\ 0\\.0035032935356663912\ \(0\)\
\-\ 30\\:\\ 0\\.0035032935356663912\ \(0\)\
\-\ defect\\:\\ 0\\.0034101783862472567\ \(0\)\
\-\ ago\\:\\ 0\\.0033909688921079408\ \(0\)\
\-\ weakness\\:\\ 0\\.0033833809733778085\ \(0\)\
\-\ clear\\:\\ 0\\.003368365259218172\ \(0\)\
\-\ non\\-contributory\\:\\ 0\\.00336464414520989\ \(0\)\
\-\ sinus\\:\\ 0\\.003331725980429038\ \(0\)\
\-\ reported\\:\\ 0\\.0033209753204432963\ \(0\)\
\-\ 20\\:\\ 0\\.0032756025971823195\ \(0\)\
\-\ complete\\:\\ 0\\.003206157712138651\ \(0\)\
\-\ to\\:\\ 0\\.0031870754361416885\ \(0\)\
\-\ new\\:\\ 0\\.0031746140477617894\ \(0\)\
\-\ inflammatory\\:\\ 0\\.0031591854415693216\ \(0\)\
\-\ side\\:\\ 0\\.0031561263345032736\ \(0\)\
\-\ inferior\\:\\ 0\\.0030909556091248003\ \(0\)\
\-\ air\\:\\ 0\\.003082369537901883\ \(0\)\
\-\ asymptomatic\\:\\ 0\\.0030795228123625664\ \(0\)\
\-\ type\\:\\ 0\\.0030710279619903095\ \(0\)\
\-\ recent\\:\\ 0\\.00306260026528763\ \(0\)\
\-\ by\\:\\ 0\\.0030338398789869396\ \(0\)\
\-\ white\\:\\ 0\\.0030214330625927695\ \(0\)\
\-\ x\\:\\ 0\\.0030054012103917665\ \(0\)\
\-\ central\\:\\ 0\\.002997474794093773\ \(0\)\
\-\ radiation\\:\\ 0\\.0029896068758660304\ \(0\)\
\-\ follow\\-up\\:\\ 0\\.0029637921017502578\ \(0\)\
\-\ injury\\:\\ 0\\.0029042734988153516\ \(0\)\
\-\ onset\\:\\ 0\\.0028757155926707354\ \(0\)\
\-\ found\\:\\ 0\\.0028710294397144053\ \(0\)\
\-\ any\\:\\ 0\\.002868694065109055\ \(0\)\
\-\ will\\:\\ 0\\.0028501929833466334\ \(0\)\
\-\ medical\\:\\ 0\\.002803102132266529\ \(0\)\
\-\ diffuse\\:\\ 0\\.0027580036464555594\ \(0\)\
\-\ brain\\:\\ 0\\.0027413129246298103\ \(0\)\
\-\ her\\:\\ 0\\.0027392448384700803\ \(0\)\
\-\ 6\\:\\ 0\\.0027208104065830217\ \(0\)\
\-\ see\\:\\ 0\\.002718781675083996\ \(0\)\
\-\ 5\\:\\ 0\\.002665416228618511\ \(0\)\
\-\ evaluation\\:\\ 0\\.0026463100168729295\ \(0\)\
\-\ y\\.o\\:\\ 0\\.0026294023801563967\ \(0\)\
\-\ s\\:\\ 0\\.0026127587069451888\ \(0\)\
\-\ changes\\:\\ 0\\.002610925347798572\ \(0\)\
\-\ when\\:\\ 0\\.0026090951360511786\ \(0\)\
\-\ weeks\\:\\ 0\\.0025855839625811817\ \(0\)\
\-\ all\\:\\ 0\\.00257667749406321\ \(0\)\
\-\ likely\\:\\ 0\\.00256960550739409\ \(0\)\
\-\ secondary\\:\\ 0\\.0025469402628025667\ \(0\)\
\-\ mass\\:\\ 0\\.002534031997756001\ \(0\)\
\-\ one\\:\\ 0\\.0024687967839132664\ \(0\)\
\-\ at\\:\\ 0\\.002468578151026936\ \(0\)\
\-\ common\\:\\ 0\\.002384080183322385\ \(0\)\
\-\ these\\:\\ 0\\.0023708365585904476\ \(0\)\
\-\ anterior\\:\\ 0\\.0023462610061436434\ \(0\)\
\-\ over\\:\\ 0\\.0023194483903411114\ \(0\)\
\-\ on\\:\\ 0\\.002315216457458725\ \(0\)\
\-\ increased\\:\\ 0\\.0022286618142853473\ \(0\)\
\-\ into\\:\\ 0\\.0021677253389762335\ \(0\)\
\-\ and\\:\\ 0\\.0021109798113586385\ \(0\)\
\-\ was\\:\\ 0\\.0021072015399012513\ \(0\)\
\-\ woman\\:\\ 0\\.002104374144444463\ \(0\)\
\-\ diagnosis\\:\\ 0\\.002091918263092132\ \(0\)\
\-\ can\\:\\ 0\\.00206633513056404\ \(0\)\
\-\ large\\:\\ 0\\.0019920495008860124\ \(0\)\
\-\ had\\:\\ 0\\.0019657247539879618\ \(0\)\
\-\ 2\\:\\ 0\\.0019617318726125226\ \(0\)\
\-\ surgical\\:\\ 0\\.0019149485823576264\ \(0\)\
\-\ treatment\\:\\ 0\\.001843941321536127\ \(0\)\
\-\ that\\:\\ 0\\.0015735402223441613\ \(0\)\
\-\ disease\\:\\ 0\\.0014890592123834798\ \(0\)\
\-\ from\\:\\ 0\\.0013501446835332753\ \(0\)\
\-\ not\\:\\ 0\\.001316437816356008\ \(0\)\
\-\ are\\:\\ 0\\.0012418698001381682\ \(0\)\
\-\ is\\:\\ 0\\.0011989142396262805\ \(0\)\
\-\ pain\\:\\ 0\\.0011125886647449198\ \(0\)\
\-\ right\\:\\ 0\\.0009612278348725124\ \(0\)\
\-\ with\\:\\ 0\\.0006236896380058089\ \(0\)\
\-\ the\\:\\ 0\\.0004421618913762019\ \(0\)\
\-\ a\\:\\ 0\\.00042281428765309306\ \(0\)\
\-\ \\.\\:\\ 0\\.0003027678984848296\ \(0\)\
